GSK will buy efimosfermin, a specialty medicine used to treat liver disease from Boston Pharmaceuticals, for up to $2 billion ...

GSK Plc agreed to buy an experimental medicine to treat liver diseases for as much as $2 billion as the UK drugmaker seeks to ...

The pharma giant will pay $1.2 billion up-front for efimosfermin, with deal including potential success-based milestone ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks ...

FILE PHOTO: UnitedHealth CEO Andrew Witty testifies before a Senate Finance Committee hearing about a recent cyberattack at ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

British pharmaceutical company GSK(GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are ...

Imperial falls in steady FTSE 100, Burberry up 9% 08:36 , Graeme Evans The FTSE 100-listed shares ...

GSK Pharma reported a 35% rise in net profit to Rs 263 crore in Q4 FY25, while Aditya Birla Capital reported a net profit of ...